Potential synergy between PSMA uptake and tumour blood flow for prediction of human prostate cancer aggressiveness
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2191-219X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Potential synergy between PSMA uptake and tumour blood flow for prediction of human prostate cancer aggressiveness ; volume:11 ; number:1 ; day:9 ; month:2 ; year:2021 ; pages:1-11 ; date:12.2021
EJNMMI Research ; 11, Heft 1 (9.2.2021), 1-11, 12.2021
- Creator
-
Jochumsen, Mads Ryø
Sörensen, Jens
Tolbod, Lars Poulsen
Pedersen, Bodil Ginnerup
Frøkiær, Jørgen
Borre, Michael
Bouchelouche, Kirsten
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13550-021-00757-y
- URN
-
urn:nbn:de:101:1-2021042120241812017813
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
- 14.08.2025, 10:59 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Jochumsen, Mads Ryø
- Sörensen, Jens
- Tolbod, Lars Poulsen
- Pedersen, Bodil Ginnerup
- Frøkiær, Jørgen
- Borre, Michael
- Bouchelouche, Kirsten
- SpringerLink (Online service)
Other Objects (12)
18F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617
PSMA expression level predicts differentiated thyroid cancer aggressiveness and patient outcome
Antihormone treatment differentially regulates PSA secretion, PSMA expression and 68Ga–PSMA uptake in LNCaP cells
Total 18F-dopa PET tumour uptake reflects metabolic endocrine tumour activity in patients with a carcinoid tumour
Aggressiveness and Redistribution
p53 suppresses type II endometrial carcinomas in mice and governs endometrial tumour aggressiveness in humans
Oral pimonidazole unveils clinicopathologic and epigenetic features of hypoxic tumour aggressiveness in localized prostate cancer
Bone marrow impairment during early [177Lu]PSMA-617 radioligand therapy: Haematotoxicity or tumour progression?
Flare on [18F]PSMA-1007 PET/CT after short-term androgen deprivation therapy and its correlation to FDG uptake: possible marker of tumor aggressiveness in treatment-naïve metastatic prostate cancer patients
What’s behind 68Ga-PSMA-11 uptake in primary prostate cancer PET? Investigation of histopathological parameters and immunohistochemical PSMA expression patterns
Heterogeneity of prostate-specific membrane antigen (PSMA) and PSMA-ligand uptake detection combining autoradiography and postoperative pathology in primary prostate cancer
The PDGF pathway in breast cancer is linked to tumour aggressiveness, triple-negative subtype and early recurrence
18F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617
PSMA expression level predicts differentiated thyroid cancer aggressiveness and patient outcome
Antihormone treatment differentially regulates PSA secretion, PSMA expression and 68Ga–PSMA uptake in LNCaP cells
Total 18F-dopa PET tumour uptake reflects metabolic endocrine tumour activity in patients with a carcinoid tumour
Aggressiveness and Redistribution
p53 suppresses type II endometrial carcinomas in mice and governs endometrial tumour aggressiveness in humans
Oral pimonidazole unveils clinicopathologic and epigenetic features of hypoxic tumour aggressiveness in localized prostate cancer
Bone marrow impairment during early [177Lu]PSMA-617 radioligand therapy: Haematotoxicity or tumour progression?
Flare on [18F]PSMA-1007 PET/CT after short-term androgen deprivation therapy and its correlation to FDG uptake: possible marker of tumor aggressiveness in treatment-naïve metastatic prostate cancer patients
What’s behind 68Ga-PSMA-11 uptake in primary prostate cancer PET? Investigation of histopathological parameters and immunohistochemical PSMA expression patterns
Heterogeneity of prostate-specific membrane antigen (PSMA) and PSMA-ligand uptake detection combining autoradiography and postoperative pathology in primary prostate cancer
The PDGF pathway in breast cancer is linked to tumour aggressiveness, triple-negative subtype and early recurrence
18F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617
PSMA expression level predicts differentiated thyroid cancer aggressiveness and patient outcome
Antihormone treatment differentially regulates PSA secretion, PSMA expression and 68Ga–PSMA uptake in LNCaP cells
Total 18F-dopa PET tumour uptake reflects metabolic endocrine tumour activity in patients with a carcinoid tumour
Aggressiveness and Redistribution
p53 suppresses type II endometrial carcinomas in mice and governs endometrial tumour aggressiveness in humans
Oral pimonidazole unveils clinicopathologic and epigenetic features of hypoxic tumour aggressiveness in localized prostate cancer
Bone marrow impairment during early [177Lu]PSMA-617 radioligand therapy: Haematotoxicity or tumour progression?
Flare on [18F]PSMA-1007 PET/CT after short-term androgen deprivation therapy and its correlation to FDG uptake: possible marker of tumor aggressiveness in treatment-naïve metastatic prostate cancer patients
What’s behind 68Ga-PSMA-11 uptake in primary prostate cancer PET? Investigation of histopathological parameters and immunohistochemical PSMA expression patterns
Heterogeneity of prostate-specific membrane antigen (PSMA) and PSMA-ligand uptake detection combining autoradiography and postoperative pathology in primary prostate cancer